Lisa Cook sues Trump over firing attempt, emergency hearing set
BOSTON - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company, has announced new clinical data from its Phase 2 trial of stenoparib in advanced ovarian cancer, presented at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer in Seattle, Washington.
The trial focused on stenoparib, a novel dual PARP/Wnt pathway inhibitor, and its effectiveness in patients with platinum-resistant or refractory ovarian cancer. These patients typically have limited treatment options and face a high likelihood of disease recurrence. However, the study showed that some patients experienced prolonged therapy benefits, with one patient achieving a complete response lasting over 10 months. While the clinical results are promising, InvestingPro data shows the company holds more cash than debt on its balance sheet, with a current ratio of 2.75, providing some financial flexibility for continued development. Discover 8 more exclusive InvestingPro Tips about ALLR’s financial position and market performance.
Dr. Fernanda B. Musa, MD, MS, the Director of Clinical Trials in Gynecologic Oncology at Providence-Swedish Cancer Institute and the study’s presenter, noted the importance of these findings for patients with limited therapeutic options, particularly those without BRCA mutations, who generally do not benefit from first-generation PARP inhibitors.
The study reported that stenoparib was well-tolerated and did not induce the bone marrow toxicity typically associated with first-generation PARP inhibitors. This suggests a potential new treatment avenue for a broader group of patients.
Thomas Jensen, CEO of Allarity Therapeutics, expressed optimism about the results, emphasizing the drug’s dual action on both PARP and Tankyrase targets and its potential for durable clinical benefit in heavily pre-treated patients. He also highlighted the significance of the data in guiding a new protocol aimed at further understanding stenoparib’s mechanism and advancing it toward regulatory approval.
The data also indicated clinical benefits for patients with different genetic backgrounds, including those with and without BRCA mutations. This could have implications for the larger patient group without BRCA mutations.
Stenoparib, developed by Allarity Therapeutics, is an orally available small-molecule that inhibits both PARP1/2 and tankyrase 1/2, with potential therapeutic implications for various cancer types. The company has acquired exclusive global rights for the drug’s development and commercialization. Despite the stock’s significant decline of 99.54% over the past year, InvestingPro’s Fair Value analysis suggests the stock is currently undervalued. Get detailed valuation metrics and comprehensive financial analysis with an InvestingPro subscription.
This press release is based on a statement from Allarity Therapeutics and does not constitute an endorsement of the company or its products. The information presented is for educational purposes only and is not a recommendation for investment or medical decisions.
In other recent news, Allarity Therapeutics has concluded a settlement with the U.S. Securities and Exchange Commission (SEC) concerning its past disclosures to the FDA. The settlement involves a $2.5 million civil penalty, and the company has agreed to an administrative cease-and-desist order without admitting or denying the SEC’s findings. This development allows Allarity to concentrate on advancing its clinical programs, particularly the development of stenoparib, a dual-targeted inhibitor for cancer treatment. The company has announced a new protocol for its ongoing clinical trial of stenoparib, focusing on patients with advanced, recurrent, platinum-resistant ovarian cancer. The trial aims to refine patient selection and dosage to enhance the drug’s effectiveness and support regulatory approval efforts. Allarity is also working on improving its Drug Response Predictor (DRP®) platform, which could serve as a companion diagnostic for stenoparib. The company has reported sustained clinical benefits from stenoparib in some patients, leading to an accelerated regulatory path for its development. Patient enrollment for this new trial protocol is anticipated to begin in the first half of 2025, with initial recruitment at leading U.S. sites.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.